Skip Ribbon Commands
Skip to main content
Cellular Therapy & Immunobiology


The mission of the Cellular Therapy & Immunobiology Working Party is to understand and exploit the biological including immunological events occurring upon haematopoietic stem cell transplantation at large, and to implement modern cellular therapies based on cell and gene engineering approaches to improve transplantation outcomes.

Cellular Therapy is an emerging medical science that is today facing a unique developmental phase, well documented by the outstanding and growing numbers of clinical trials. Such an exponential growth requires proper infrastructures, cell repositories, clinical registries, technical and regulatory guidelines for appropriate cell manipulation and validation of the innovative therapeutic approaches in multicentric clinical trials.

The CTIWP aims at fostering cellular therapy in Europe, through a continuous crosstalk between basic science findings, transplant immunobiology observations and implementation of cellular manufacturing approaches designed to answer unmet medical needs.

To this aim we will actively implement:

  1. Retrospective and multicentric prospective transplant immunobiology studies
  2. Retrospective and multicentric prospective clinical trials of cell/gene therapy
  3. A map of European Centers active in cell manipulation and cell therapy
  4. A dedicated registry for cellular products and clinical trials of cell and cell-based gene therapy.

These aims will be pursued through the activity of WP subcommittees and through an active collaboration with International and European Societies of Transplantation, Cell/Gene Therapy and with major investors in the field.


Educational Event of CMWP and CTIWP: "Come of age : Immunotherapy in Multiple Myeloma”. 30 September to 1 October 2016 in Berlin, Germany


Chiara Bonini 

Christian Chabannon 

The CTIWP studies are allocated to the EBMT Data Office Leiden:

​Steffie van der Werf​ ​Study Coordinator​

Subcommitte Leaders:

​Antoine Toubert​ ​Transplant Immunobiology
Annalisa Ruggeri​ ​Cord blood immunobiology
Attilio Bondanza​ ​Cancer immunotherapy
​Katharina Fleischhauer
Vanderson Rocha
Francesco Dazzi​ ​Immune tolerance


Immune reconstitution

Survey to evaluate and summarize advances in immune recovery after allogeneic HSCT, focusing on the recovered immune subsets likely to have the greatest impact on clinical outcomes. We would appreciate if you could answer to the following questions in appendix-I, to help us designing a proper retrospective study concerning the monitoring of post-transplant immune reconstitution.

Jon J. van Rood Award  @ EBMT 2017

Best Paper in the Immunology of Allogeneic Hematopoietic Transplantation in the Cellular Therapy and Immunobiology Working Party

The induction of immunological tolerance is a major task for the success of organ and stem cell transplantation. Selection of the best donor and adequate immune suppression of both rejection and graft-versus-host reaction are fundamental to the success of transplantation. However, graft-versus-leukaemia/tumour reactions are crucial for the success of the treatment of leukaemia, lymphoma and myeloma with allogeneic stem cell transplantation. Antigenic targets and effector cells play a major role in tolerance and graft-versus-leukaemia/tumour reactions.
Keen to foster scientific research in this area, the EBMT Cellular Therapy and Immunobiology Working Party is pleased to offer this prestigious (€ 5,000) award for outstanding contributions in the field of hematopoietic transplantation immunology, immunogenetics, cellular therapy, tolerance and graft-vs-leukaemia/tumour effects. The selection will be undertaken by a distinguished international jury under the supervision of Prof. Jon J. van Rood.
The award is presented on an annual basis in the Cellular Therapy and Immunobiology Working Party Sessions at the EBMT Annual Meeting.
To qualify for the award your paper should be published or accepted for publication during the year 2016 and candidates should be not older than 40 years. Applications for the award should include the paper and the CV of the applicant, which should be submitted by email to: by:
January 22nd 2017
This award is generously supported by EBMT with an unrestricted educational grant of € 5,000.

Related documents

Click HERE to view the publication list

 HLA identification page for the two combined retrospective studies on haploidentical stem cell transplantation in AML and ALL 

Studies coordinated by the CTIWP

Click HERE to view the Current Research list

How to get involved?

Please contact the Chairperson or the Secretary.​



The EBMT implements Elsevier’s MACRO platform to upgrade patient registry.... Read more >>
​EBMT TV returns to 2017 Annual Meeting...
​The EBMT has contributed to the Innovative Medicines Intiative... Read more >>
​More than 60 EBMT centres have already started entering their related donor data. We want to invite... Read more >>


Bookmark and Share